Gleevec/Glivec市場規模、佔有率和成長分析：按劑型、含量、適應症、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球Gleevec/Glivec市場價值為 24.2 億美元，預計到 2025 年將成長至 26.2 億美元，到 2033 年將成長至 49.6 億美元，在預測期（2026-2033 年）內複合年成長率為 8.3%。

Gleevec/Glivec已成為治療慢性骨髓性白血病和胃腸道基質腫瘤的關鍵標靶治療，形成了一個具有重要臨床價值的醫藥市場。Imatinib市場涵蓋品牌藥和非專利藥，並在全球腫瘤診所、醫院和國家治療計畫中廣泛使用。Gleevec/Glivec的療效使慢性骨髓性白血病從一種不治之症轉變為一種可控疾病，從而帶來了持續的需求。專利到期加劇了學名藥的競爭，降低了單價，減輕了中低收入國家患者的經濟負擔，並加快了治療的普及。生產商正在利用差異化製劑和創新的生命週期策略，而第三方支付和診斷能力的提升則為競標和地理市場擴張創造了更多機會，最終將提高患者的長期生存率。

全球Gleevec/Glivec市場按劑型、劑量組成、適應症、分銷管道、最終用戶和地區進行細分。依劑型分類，市場分為口服錠劑、口服液和其他劑型。依劑量組成分類，市場分為100毫克、400毫克和其他劑量。依適應症分類，市場分為慢性骨髓性白血病、胃腸道基質腫瘤和其他適應症。按分銷管道分類，市場分為醫院藥房、零售藥房、專科線上藥房和其他管道。依最終用戶分類，市場分為專科癌症中心、綜合醫院和其他最終用戶。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球Gleevec/Glivec市場的成長要素

全球Gleevec/Glivec市場的主要促進因素之一是慢性骨髓性白血病(CML) 和胃腸道基質腫瘤(GIST) 的日益普遍，而Gleevec/Glivec（Imatinib）可有效治療這兩種疾病。隨著人們對這些疾病的認知不斷提高以及診斷能力的進步，越來越多的患者得以確診並接受治療，從而增加了對標靶治療的需求。此外，對個人化醫療的日益重視以及伴隨診斷技術的開發，進一步完善了治療方案並擴大了患者群體。隨著醫療保健系統不斷發展以支持先進的腫瘤治療，Gleevec/Glivec仍然是標靶癌症治療的基石，對市場成長產生了積極影響。

全球Gleevec/Glivec市場的限制因素

全球Gleevec/Glivec市場的主要限制因素之一是來自學名藥日益激烈的競爭。隨著Gleevec/Glivec專利到期和生物相似藥的上市，市場在價格和市場佔有率方面面臨巨大的壓力。這種競爭可能導致原廠藥生產商的收入減少和促銷預算受限，進而影響新治療方法的研發活動。此外，不同地區學名藥核准時間的差異可能會構成市場准入壁壘，進一步加劇競爭。因此，更經濟實惠的治療方案的出現可能會導致醫療專業人員和患者對Gleevec/Glivec的需求下降。

全球Gleevec/Glivec市場趨勢

全球Gleevec/Glivec市場正經歷著向創新、精準標靶治療的動態轉變，以治療慢性骨髓性白血病。製造商日益專注於開發新型製劑、聯合治療和以患者為中心的給藥系統，以提高耐受性並確保長期用藥依從性。生技公司與學術機構之間的舉措正在加速轉化研究的進展，並將生物標記整合到治療方案中，從而改善患者的治療效果。這種不斷變化的市場格局不僅為成熟品牌提供了差異化機遇，也強化了其在治療方案中的高階定位，從而為有效的生命週期管理和在全球範圍內增強商業性韌性鋪平了道路。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

Gleevec/Glivec全球市場規模：以劑型分類

• 口服錠劑
• 口服液
• 其他

全球Gleevec/Glivec市場規模：依含量

• 100毫克
• 400毫克
• 其他

全球Gleevec/Glivec市場規模：依適應症分類

• 慢性骨髓性白血病
• 胃腸道基質腫瘤
• 其他

全球Gleevec/Glivec市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 專業網路藥房
• 其他

全球Gleevec/Glivec市場規模：依最終用戶分類

• 專科癌症中心
• 綜合醫院
• 其他

全球Gleevec/Glivec市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novartis
• Teva Pharmaceutical
• Sun Pharmaceutical
• Cipla
• Dr. Reddy's Laboratories
• Lupin
• Natco Pharma
• Apotex
• Glenmark Pharmaceuticals
• Hetero Drugs
• Macleods Pharmaceuticals
• Zydus Lifesciences
• Aurobindo Pharma
• Biocon
• Accord Healthcare
• Sandoz
• Viatris
• Torrent Pharmaceuticals
• Alkem Laboratories
• Shilpa Medicare

結論與建議

Global Gleevec Market size was valued at USD 2.42 Billion in 2024 and is poised to grow from USD 2.62 Billion in 2025 to USD 4.96 Billion by 2033, growing at a CAGR of 8.3% during the forecast period (2026-2033).

Gleevec has established itself as a pivotal targeted therapy for chronic myeloid leukemia and gastrointestinal stromal tumors, creating a pharmaceutical market with significant clinical value. The imatinib market encompasses both brand-name and generic formulations, widely utilized across oncology clinics, hospitals, and national treatment programs globally. A sustained demand persists due to Gleevec's efficacy in transforming chronic myeloid leukemia from a terminal illness to a manageable condition. Patent expirations have spurred generic competition, reducing unit prices and enhancing affordability for patients in low- and middle-income countries, resulting in increased treatment uptake. Manufacturers are capitalizing on differentiated formulations and innovative lifecycle strategies, while third-party payments and improved diagnostic capabilities present further opportunities in tender procurement and geographic market expansion, ultimately improving long-term survivorship outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gleevec market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gleevec Market Segments Analysis

Global gleevec market is segmented by dosage form, strength configuration,indication, distribution channel,end-userand region. Based on dosage form, the market is segmented into oral tablets, oralsolutionsand others. Based on strength configuration, the market is segmented into 100 milligrams, 400 milligrams and others. Based onindication, the market is segmented into chronic myeloidleukemia, gastrointestinal stromaltumorsand others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, specialty onlinepharmaciesand others. Based on end-user, the market is segmented into specialized oncologycenters, multi-specialtyhospitalsand others. Based on region, the market is segmented into North America, Europe, Asia Pacific, LatinAmerica and Middle East & Africa.

Driver of the Global Gleevec Market

One key market driver for the global Gleevec market is the increasing prevalence of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), which are effectively treated with Gleevec (imatinib). As awareness of these conditions rises and diagnostic capabilities improve, more patients are being identified and treated, thereby boosting demand for targeted therapies. Additionally, the growing emphasis on personalized medicine and the development of companion diagnostics further enhance treatment protocols, creating a larger patient base. As healthcare systems evolve to support advanced oncology therapies, Gleevec remains a cornerstone in targeted cancer treatments, influencing market growth positively.

Restraints in the Global Gleevec Market

One key market restraint for the Global Gleevec Market is the increasing prevalence of generic competition. As patents for Gleevec expire and biosimilar alternatives are introduced, the market faces significant pressure on pricing and market share. This competition can lead to reduced revenues for original manufacturers and limitations on promotional budgets, thereby impacting research and development efforts for new therapies. Additionally, varying regulatory approval timelines for generics across different regions can create market entry barriers, further intensifying competition. Consequently, the availability of more affordable treatment options may lead to decreased adoption of Gleevec among healthcare providers and patients.

Market Trends of the Global Gleevec Market

The Global Gleevec market is witnessing a dynamic shift towards innovative targeted therapies that prioritize precision in treating chronic myeloid leukemia. Manufacturers are increasingly focused on developing novel formulations, combination strategies, and patient-centric delivery systems to enhance tolerability and ensure long-term adherence. Collaborative initiatives between biotechnology firms and academic institutions are fostering advancements in translational studies and integrating biomarkers for better patient outcomes. This evolving landscape not only presents differentiation opportunities for established brands but also strengthens their premium positioning in treatment protocols, thereby creating pathways for effective lifecycle management and promoting robust commercial resilience on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Gleevec Market Size by Dosage Form & CAGR (2026-2033)

• Market Overview
• Oral Tablets
• Oral Solutions
• Others

Global Gleevec Market Size by Strength Configuration & CAGR (2026-2033)

• Market Overview
• 100 Milligrams
• 400 Milligrams
• Others

Global Gleevec Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Chronic Myeloid Leukemia
• Gastrointestinal Stromal Tumors
• Others

Global Gleevec Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Online Pharmacies
• Others

Global Gleevec Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Specialized Oncology Centers
• Multi-Specialty Hospitals
• Others

Global Gleevec Market Size & CAGR (2026-2033)

• North America (Dosage Form, Strength Configuration, Indication, Distribution Channel, End-User)
  • US
  • Canada
• Europe (Dosage Form, Strength Configuration, Indication, Distribution Channel, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Dosage Form, Strength Configuration, Indication, Distribution Channel, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Dosage Form, Strength Configuration, Indication, Distribution Channel, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Dosage Form, Strength Configuration, Indication, Distribution Channel, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natco Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero Drugs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macleods Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accord Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shilpa Medicare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations